Imfinzi is first and only immunotherapy to show survival benefit in ...
Jun 2, 2024 · Imfinzi is the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiation therapy.
Imfinzi Improves Survival in Small Cell Lung Cancer - NCI
Jun 25, 2024 · The immunotherapy drug durvalumab (Imfinzi) helped people with early-stage small cell lung cancer live longer, according to initial results from a large clinical trial. Durvalumab is a type of immunotherapy called an immune checkpoint inhibitor.
Update on ADJUVANT BR.31 Phase III trial of Imfinzi in ... - AstraZeneca
Jun 25, 2024 · Patients were randomised 2:1 to receive a 20mg/kg IV infusion of Imfinzi or placebo every four weeks for up to 48 weeks. The trial is being conducted at 269 centres across 19 countries and regions including in Canada, the US, Australia, Europe and Asia.
IMFINZI® (durvalumab) significantly improved overall survival …
Apr 5, 2024 · First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial. Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS ...
IMFINZI® (durvalumab) is the first and only immunotherapy to …
Jun 2, 2024 · IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs....
FDA approves neoadjuvant/adjuvant durvalumab for resectable …
On August 15, 2024, the FDA approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment...
FDA expands approval of Imfinzi to reduce the risk of non-small …
The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be...
Imfinzi significantly improved overall survival and progression …
Apr 5, 2024 · Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial. PUBLISHED 5 April 2024. First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial. Positive high-level results of the ADRIATIC Phase III ...
ASCO: AZ's latest Tagrisso data receive standing ovation - Fierce …
Jun 3, 2024 · Imfinzi reduced the risk of death by 27% compared with placebo in patients with limited-stage small cell lung cancer (LS-SCLC) following concurrent chemoradiotherapy, according to results...
IMFINZI® (durvalumab) granted Priority Review and …
WILMINGTON, Del., August 15, 2024 -- (BUSINESS WIRE)--AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI ® (durvalumab), based on the results from the positive ADRIATIC...